Related Article

This CCR Translation refers to the following Article:
Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Richard S. Finn, Yoon-Koo Kang, Mary Mulcahy, Blase N. Polite, Ho Yeong Lim, Ian Walters, Christine Baudelet, Demetrios Manekas, and Joong-Won Park